Partnerships in Personalized Medicine for In Vitro Diagnostic Industry

Seeking partners and establishing strong relationships, developing realistic goals and timelines and
maximizing results for diagnostics in corporate partnerships

April 20-21, 2009

San Mateo, CA

The emerging environment for life sciences is changing drastically with costs cuts threatening new innovations. Critical advantages can be observed when drug or device manufacturers join forces with diagnostic companies to develop new therapies, improve clinical research and allow physicians to prescribe more effectively.

These partnerships do not come without complications and complex challenges. Both organizations must have a clear action plan and expectations. This conference will highlight tools and best practices for these partnerships through case studies and perspectives from several key industry leaders.

This two-day program will feature 17 sessions including:

Diagnostic Company Perspective:
Negotiating Alliances With Potential Partners: Showing Value on Both Sides
Jonathan Cohen, CEO, 20/20 GeneSystems, Inc.

Pharmaceutical Perspective:
What Is Attractive in Potential Partnerships
Andrea H. Lauber PhD, Strategic Transactions Group, Bristol-Myers Squibb Company

Regulatory Perspective:
The Future Pathways for Companion Diagnostics
Alberto Gutierrez, PhD, Deputy Director, New Product Evaluation
Office of In VitroxDiagnostic Device (OIVD) Evaluation and Safety FDA

Additional Presenting Companies Include

• Arcxis Biotechnologies
• Atherotech
• Axial Biotech
• Ensemble Discovery
• Genelex
• Luminex Corporation
• ParagonDx
• Quest Diagnostics Clinical Trials
• Scientia Advisors
• Theranostics Health
• Xhale, Inc.

For the full conference agenda, registration details, and information on promotional pricing please contact:
Paul Hernandez, Marketing Manager
phernandez@Q1productions.com
312-602-9684